The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Lysopadol Mint 20mg Lozenges

20 milligram(s) Lozenge

Sanofi-Aventis Ireland Limited T/A SANOFIPA0540/186/001

Main Information

Trade NameLysopadol Mint 20mg Lozenges
Active SubstancesAMBROXOL HYDROCHLORIDE
Strength20 milligram(s)
Dosage FormLozenge
Licence HolderSanofi-Aventis Ireland Limited T/A SANOFI
Licence NumberPA0540/186/001

Group Information

ATC CodeR05CB Mucolytics
R05CB06 ambroxol

Status

Authorised/WithdrawnAuthorised
Licence Issued10/02/2004
Legal statusProduct not subject to medical prescription
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to the general public
Conditions of Licence
Marketing StatusNot marketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletNo document available
Public Assessment ReportNo document available
« Back